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allele A in the study group was 8%, in the control group – 4% (р = 0.1; 
chi-square). The following genotypes distribution was observed in the 
study group: АА – 0.02; AG – 0.13; GG – 0.85. In the control group the 
following genotype distribution was observed: АА – 0.01; AG – 0.05; 
GG – 0.94. Distributions corresponded to Hardy-Weinberg equilibrium.
Conclusion: In our prospective study, we observed tendency to genetic 
predisposition to higher activity of CYP3A5 in women with stillbirth 
compared with matched women with normal pregnancy. The results, 
however, did not reach statistical significance, which may demonstrate 
either lack of real association or insufficient number of subjects recruited. 
The observation needs to be proved or disproved in a larger population.
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Introduction: Venlafaxine, as a substrate of p-glycoprotein, is a 
widely used serotonin-noradrenaline reuptake inhibitor (SNRI). The 
aim of the study is to investigate the influence of ABCB1 G2677T/A, 
C3435T polymorphisms on efficacy of venlafaxine.
Patients (or Materials) and Methods: Patients (n = 52) who met 
the Diagnostic and Statistical Manual of Mental Disorders Fourth 
Edition-IV criteria for major depressive disorder (MDD) were 
enrolled the study. All patients had affirmed for once a day adminis-
tration of venlafaxine at 8:00 to 9:00 am during the study. Protocol 
visits were completed at baseline, 1st, 2nd, 4th, and 6th weeks. 
The clinical response to venlafaxine was evaluated by psychiatrists 
with 17-item Hamilton Rating Scale for Depression (HAM-D17). 
Blood samples were taken for genotyping at 4th week of the study. 
Genotyping for the ABCB1 gene 3435C> T and G2677T/A polymor-
phisms was performed by PCR/RFLP assays.
Results: Our results showed that there is no correlation between effi-
cacy and tolerability of venlafaxine and ABCB1 G2677T/A, C3435T 
polymorphisms. But carriers of the TT genotype for 3435C> T poly-
morphism and carriers of the TT/TA genotype for G2677T/A poly-
morphism could be tended to be poor responder (Table).
Conclusion: Although our results showed that there is no correlation 
between efficacy of venlafaxine and ABCB1 G2677T/A, C3435T pol-
ymorphisms, we couldn’t reach the sufficient patient number. There is 
need for studies with sufficient patient number and haplotype analysis 
including also ABCB1 C1236T polymorphism in MDD patients.
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Introduction: The promise of personalized care has not always 
translated into improvements in patient care. There are concerns 
among payers that advice for certain genetic tests has been revoked, 
diagnostic tests can be costly, and there is fragmentation of funding 
of care including tests. In addition, pharmaceutical companies are 
seeking high prices for new targeted drugs through designating them 
as orphan drugs. Consequently, there is a need to integrate current 
knowledge about the value of genetic, biomarkers, prognostic tests 
and targeted drug therapies from a health authority perspective to 
provide future guidance.
Patients (or Materials) and Methods: This will be achieved by (1) 
reviewing the current literature regarding personalized medicine; 
(2) appraising key funding, organizational, and health care issues 
that need to be addressed especially from a health authority per-
spective; and (3) suggesting future avenues for all key stakeholder 
groups to enhance future funding and utilization of new personalized 
approaches to improve future patient care. The latter will be achieved 
through an iterative process.
Results: Multiple findings are consolidated under headings. These 
include (1) general considerations incorporating definitions and the 
need for different approaches to progress personalized medicine; (2) 
knowledge about the influence of pharmacogenomics on response 
and toxicity of drug therapies using current examples including cases 
where recommendations have recently been revoked; (3) knowledge 
of the value of biomarker tests to target treatment approaches; (4) 
challenges and concerns including the potentially high cost of tests 
and targeted therapies and current fragmentation of funding; and 
(5) key issues for health care funding bodies to address to enhance 
funding for new diagnostic/prognostic tests as well as new targeted 
therapies. Guidance is given on potential ways forward for all key 
stakeholder groups including reviewing key medical, ethical, legal, 
Table.  HAMD17 scores according to ABCB1 G2677T/A, C3435T 
genotypes.
3435C> T 2677G> T/a
CC-CT TT GG-GT-Ga TT-Ta
n 41 11 41 11
HAMD17, baseline 21.56 ± 0.695 22.45 ± 2.077 21.78 ± 0.737 21.64 ± 1.865
HAMD17,
1st week 14.93 ± 0.851 16.73 ± 2.195 15.34 ± 0.852 15.18 ± 2.252
HAMD17,
2nd week 13.76 ±0.939 15.64 ± 1.820 13.59 ± 0.907 16.27 ± 1.978
HAMD17,
4th week 11.27 ± 0.968 11.54 ± 1.883 11.24 ± 0.931 12.36 ± 2.125
HAMD17,
6th week 9.63 ± 1.11 10.09 ± 2.095 9.54 ± 1.038 10.45 ± 2.577
F = 0.41, P = 0.741 F = 0.672, P = 0.563
